Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-01-13
2010-06-29
Long, Scott (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093200, C435S456000
Reexamination Certificate
active
07745416
ABSTRACT:
A method for regulating in vivo calcium transport in cardiac muscle of animals suffering from congestive heart failure is disclosed. According to the method, calcium ATPase activity (which decreases as congestive heart failure develops) and cardiac muscle contractility augmented by delivering a gene which operatively encodes the enzyme into the heart. Delivery systems, including but not limited to using adeno-associated viral vectors are provided. Methods for monitoring the expression and effect of the gene product on cardiac performance are also provided.
REFERENCES:
patent: 4797368 (1989-01-01), Carter et al.
patent: 5173414 (1992-12-01), Lebkowski et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5474935 (1995-12-01), Chatterjee
patent: 5589377 (1996-12-01), Lebkowski et al.
patent: 5656465 (1997-08-01), Panicali et al.
patent: 5658785 (1997-08-01), Johnson
patent: 5797870 (1998-08-01), March et al.
patent: 5858351 (1999-01-01), Podsakoff et al.
patent: 5919449 (1999-07-01), Dinsmore
patent: 6162796 (2000-12-01), Kaplitt et al.
patent: 6211163 (2001-04-01), Podsakoff et al.
patent: 6306830 (2001-10-01), Hammond et al.
patent: 6325998 (2001-12-01), Podsakoff et al.
patent: 6335011 (2002-01-01), Podsakoff et al.
patent: 6605274 (2003-08-01), Dillmann et al.
patent: 6610290 (2003-08-01), Podsakoff et al.
patent: 7078387 (2006-07-01), Leiden et al.
patent: 7291604 (2007-11-01), Hajjar et al.
patent: 7399750 (2008-07-01), Chien et al.
patent: 2002/0159978 (2002-10-01), Allen
patent: 1 232 759 (2002-08-01), None
patent: WO 96/32139 (1996-10-01), None
patent: WO 00/38518 (2000-07-01), None
patent: WO 02/22177 (2002-03-01), None
patent: WO 02/063025 (2002-08-01), None
Fraley et al., “Sustained sarcoplasmic reticulum Ca 2+-ATPase 2A transgene expression mediated by AAV results in improved contractility in a mouse moudel of decreased cardiac function,” Circulation 106 (19 Suppl.): II-31, abst. 153, Nov. 5, 2002.
Hoshijima et al. “Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery,” Nature Med. 8 (8): 864-871, Aug. 2002.
Agrawal et al., “Localized delivery of adeno-associated virus vector expressing human extracellular superoxide dismutase gene confers long term protection against ischemia-reperfusion injury . . . ,” Circulation 104 (17) : II-36, abst. 168, Oct. 23, 2001.
Orkin et al. ‘Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy,’ issued by the U.S. National Institutes of Health, Bethesda, MD, Dec. 7, 1995.
Petrof et al., “Impairment of force generation after adenovirus-mediated gene trnasfer to muscle is alleviated by adenoviral inactivation and host CD8+ T cell deficiency,” Hum. Gene Ther. 7: 1813-1826, 1996.
Verma et al. , “Gene therapy—promises, problems and prospects,” Nature 389: 239-242, Sep. 1997.
Crystal, R.G., “The gene as the drug,” Nature Med. 1(1): 15-17, Jan. 1995.
Wang et al., “A packaging cell line for propagation of recombinant adenovirus vectors contianing two lethal deletions,” Gene Ther. 2: 775-783, 1995.
Coghlan, A., “Gene dream fades away,” New Scientist, pp. 14-15, Nov. 25, 1995.
Brown, D., “Gene therapy ‘oversold’ by researchers, journalists,” Washington Post, pp. A1 and A22, Dec. 8, 1995.
Friedmann, T., “Overcoming the obstacles,” Scientific American, Jun. 1997, pp. 96-101.
Chien, K.R., “Molecular advances in cardiovascular biology,” Science 260: 916-917, May 1993.
Barinaga, M., “Gene therapy for clogged arteries passes test in pigs,” Science 265: 738, Aug. 1994.
Wattanapitayakul et al. (Biomed & Pharmacother 2000; 54: 487-504).
Del Monte et al. (Circulation 1999; 100: 2308-2311).
Tal (Journal of Biomedical Science. 2000; 7:279-291).
C. Link, Jr., et al., “Phase I Trial of In Vivo Gene Therapy with the Herpes Simplex Thymidine Kinase/Ganciclovir System for the Treatment of Refractory or Recurrent Ovarian Cancer”, pp. 1161-1179; Human Gene Therapy, vol. 7, No. 9, Jun. 10, 1996.
D. Klatzmann, et al., “Gene Therapy for Metastatic Malignant Melanoma: Evaluation of Tolerance to Intratumoral Injection of Cells Producing Recombinant Retroviruses Carrying the Herpes Simplex Virus Type 1 Thymidine Kinase Gene, to be Followed by Ganciclovir Administration”, pp. 255-267; Human Gene Therapy, vol. 7, No. 2, Jan. 20, 1996.
J. Deshane, et al., “Transductional Efficacy and Safety of an Intraperitoneally Delivered Adenovirus Encoding an Anti-erb8-2 Intracellular Single-Chain Antibody for Ovarian Cancer Gene Therapy”, pp. 378-385, Gynecology Oncology, vol. 64, No. 3, Mar. 1997.
C. H. Evans, et al., “The Promise of a New Clinical Trial—Intra-articular IL-1 Receptor Antagonist”, pp. 1-5, Proceedings of the Association of American Physicians, vol. 108, No. 1, 1996.
S. E. Raper, et al., “Safety and Feasibility of Liver-Directed Ex Vivo Gene Therapy for Homozygous Familial Hypercholesterolemia”, pp. 116-126, Annals of Surgery, vol. 223, No. 2, Feb. 1996.
T. Tursz, et al., “Phase I Study of a Recombinant Adenovirus-Mediated Gene Transfer in Lung Cancer Patients”, pp. 1857-1863, Journal of the National Cancer Institute, vol. 88, No. 24, Dec. 18, 1996.
T. Shimada, “Current Status and Future Prospects of Human Gene Therapy”, pp. 176-181, Acta Paediatrica Japonica (1996) 38.
G. Bellon, et al., “Aerosol Administration of a Recombinant Adenovirus Expressing CFTR to Cystic Fibrosis Patients: A Phase I Clinical Trial”, pp. 15-25, Human Gene Therapy, vol. 8, No. 1, Jan. 1, 1997.
S. Eck, et al., “Treatment of Advanced CNS Malignancies with the Recombinant Adenovirus H5.010RSVTK: A Phase I Trial”, pp. 1465-1482, Human Gene Therapy, vol. 7, No. 12, Aug. 1, 1996.
R. M. Blaese, et al., “T Lymphocyte-Directed Gene Therapy for ADA-SCID: Initial Trial Results after 4 Years”, pp. 475-480, Science, vol. 270, Oct. 20, 1995.
W. Waddill, III, et al., “Human Gene Therapy for Melanoma: CT-Guided Interstitial Injection”, pp. 63-67, American Journal of Roentgenology, vol. 169, Jul. 1997.
G. McLachlan, et al., “Laboratory and Clinical Studies in Support of Cystic Fibrosis Gene Therapy Using pCMV-CFTR-DOTAP”, pp. 1113-1123, Gene Therapy, vol. 3, No. 12, Dec. 1996.
J. Mühlhauser, et al., “Safety and Efficacy of In Vivo Gene Transfer into the Porcine Heart with Replication-Deficient, Recombinant Adenovirus Vectors”, pp. 145-153, Gene Therapy, vol. 3, No. 2, Feb. 1996.
X. Xing, et al., “Safety Studies of the Intraperitoneal Injection of E1A-liposome Complex in Mice”, pp. 238-243, Gene Therapy, vol. 2, No. 3, Mar. 1997.
D. Stephan, et al., “Gene and other Biological Therapies for Vascular Diseases”, pp. 97-110, Fundamental & Clinical Pharmacology, vol. 11, No. 2, 1997.
F. Giordano, et al., “Intracoronary Gene Transfer of Fibroblast Growth Factor-5 Increases Blood Flow and Contractile Function in an Ischemic Region of the Heart”, pp. 534-539, Nature Medicine, vol. 2, No. 5, May 1996.
T. Rothman, et al., “Heart Muscle-Specific Gene Expression Using Replication Defective Recombinant Adenovirus”, pp. 919-926, Gene Therapy, vol. 3, No. 10, Oct. 1996.
R. Hajjar, et al., “Physiological Effects of Adenoviral Gene Transfer of Sarcoplasmic Reticulum Calcium ATPase in Isolated Rat Myocytes”, pp. 423-429, American Heart Association Circulation, vol. 95, No. 2, Jan. 21, 1997.
R. Wilmott, et al., “Safety of Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator cDNA to the Lungs of Nonhuman Primates”, pp. 301-318, Human Gene Therapy, vol. 7, No. 3, Feb. 10, 1996.
H. Gilgenkrantz, et al., “Transient Expression of Gen
Dillman Wolfgang H.
Giordano Frank
Mestril Ruben
DLA Piper (LLP) US
Long Scott
The Regents of the University of California
LandOfFree
Method for in vivo regulation of cardiac muscle contractility does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for in vivo regulation of cardiac muscle contractility, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for in vivo regulation of cardiac muscle contractility will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4181117